June 23, 2017
Over 2.5 million individuals in the United States suffer from epilepsy. It is characterized by seizures which occur periodically and/or unpredictably. There is an expanding market of anti-epileptic medications (AEDs) and yet individuals with epilepsy, even those who are on treatment still experience periodic seizure recurrence. Currently available AEDs have poor solubility in aqueous and biological fluids and/ or are extremely hygroscopic. Additionally, available AEDs have unfavorable side-effects, neurotoxicity, drug interactions, and in about 30% of patients on AEDs are not effective in mitigating seizure occurrence. Therefore, there is a need for new AEDs with less unfavorable side effects that are able to mitigate seizures.
Researchers at the University of Kentucky have discovered a previously known neuromodulator, agmatine, to possess anticonvulsant properties. Agmatine is produced in the brain which serves to modulate several physiological functions. It plays a role in cell signaling by acting on N-methyl-D-aspartate (NMDA) receptors, an excitatory neurotransmitter receptor known to be involved in epilepsy. Agmatine is also known to regulate polyamine synthesis, which can also modulate NMDA receptor activity. Because of agmatine’s role in neuromodulation, it may be an innovative potential alternative drug used to prevent seizures with low toxicity levels.
Epilepsy, CNS disorders
Treats, prevents and may ameliorate disorders related to epilepsy, seizures, and other electroconvulsive disorders Agmatine is endogenous to the brain No toxic effects of agmatine were observed in testing of animal seizure models
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
united states suffer
biological fluids and/
mitigating seizure occurrence
technology solution researchers
possess anticonvulsant properties
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium